Quince Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $115,981 | $5,809 |
| Short-term investments | — | 11,943 |
| Prepaid expenses and other current assets | 7,430 | 5,144 |
| Total current assets | 123,411 | 22,896 |
| Property and equipment, net | 506 | 595 |
| Operating lease right-of-use assets | — | 453 |
| Intangible assets | — | 67,819 |
| Other assets | 78 | 1,760 |
| Total assets | $123,995 | $93,523 |
| LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $4,636 | $2,223 |
| Accrued expenses and other current liabilities | 3,864 | 10,608 |
| Current portion of debt | — | 18,026 |
| Short-term contingent consideration | — | 12,369 |
| Total current liabilities | 8,500 | 43,226 |
| Long-term operating lease liabilities | — | 330 |
| Long-term contingent consideration | — | 51,961 |
| Warrant liabilities | 6,292 | 32,150 |
| Other long-term liabilities | 716 | 1,570 |
| Total liabilities | 15,508 | 129,237 |
| Mezzanine equity: | ||
| Series C Preferred Stock, $0.001 par value, 294,370 shares and no shares designated as of June 30, 2026 and December 31, 2025, respectively; 211,301.868 and no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 143,811 | — |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.001 par value, 250,000,000 shares authorized, 1,017,063 and 278,627 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively(1) | 1 | — |
| Additional paid in capital(1) | 460,447 | 418,987 |
| Accumulated other comprehensive income | 4,255 | 5,750 |
| Accumulated deficit | (500,027) | (460,451) |
| Total stockholders’ equity (deficit) | (35,324) | (35,714) |
| Total liabilities, mezzanine equity, and stockholders’ equity (deficit) | $123,995 | $93,523 |
(1) Adjusted prior period common stock and additional paid-in-capital to reflect the 1-for-10 reverse stock split effected on April 10, 2026 and the 1-for-20 reverse stock split effected on June 29, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.